These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21075654)

  • 1. GLP-1: what is known, new and controversial in 2010?
    Burcelin R; Dejager S
    Diabetes Metab; 2010 Dec; 36(6 Pt 1):503-9. PubMed ID: 21075654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A role for the gut-to-brain GLP-1-dependent axis in the control of metabolism.
    Burcelin R; Serino M; Cabou C
    Curr Opin Pharmacol; 2009 Dec; 9(6):744-52. PubMed ID: 19800290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is known, new and controversial about GLP-1? Minutes of the 1st European GLP-1 Club Meeting, Marseille, 28-29 May 2008.
    Burcelin R;
    Diabetes Metab; 2008 Dec; 34(6 Pt 1):627-30. PubMed ID: 19026584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.
    Lee YS; Jun HS
    Metabolism; 2014 Jan; 63(1):9-19. PubMed ID: 24140094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
    Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
    J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid hepatic metabolism blunts the endocrine action of portally infused GLP-1 in male rats.
    Aulinger BA; Perabo M; Seeley RJ; Parhofer KG; D'Alessio DA
    Am J Physiol Endocrinol Metab; 2020 Feb; 318(2):E189-E197. PubMed ID: 31743041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2007 Apr; 62(4):217-21. PubMed ID: 17566392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New therapeutic approach in patients with type 2 diabetes based on glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP)].
    Kluz J; Adamiec R
    Postepy Hig Med Dosw (Online); 2006; 60():15-23. PubMed ID: 16407790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The insulinotropic effect of exogenous glucagon-like peptide-1 is not affected by acute vagotomy in anaesthetized pigs.
    Veedfald S; Hansen M; Christensen LW; Larsen SA; Hjøllund KR; Plamboeck A; Hartmann B; Deacon CF; Holst JJ
    Exp Physiol; 2016 Jul; 101(7):895-912. PubMed ID: 27027735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
    Green BD; Gault VA; O'Harte FP; Flatt PR
    Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered beta-cells secreting dipeptidyl peptidase IV-resistant glucagon-like peptide-1 show enhanced glucose-responsiveness.
    Islam MS; Rahman SA; Mirzaei Z; Islam KB
    Life Sci; 2005 Jan; 76(11):1239-48. PubMed ID: 15642594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-Like Peptide 1 Analogs and their Effects on Pancreatic Islets.
    Tudurí E; López M; Diéguez C; Nadal A; Nogueiras R
    Trends Endocrinol Metab; 2016 May; 27(5):304-318. PubMed ID: 27062006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is GLP-1 a hormone: Whether and When?
    D'Alessio D
    J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):50-5. PubMed ID: 27186356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. cAMP-independent effects of GLP-1 on β cells.
    Kolic J; MacDonald PE
    J Clin Invest; 2015 Dec; 125(12):4327-30. PubMed ID: 26571393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 and type 2 diabetes: physiology and new clinical advances.
    Combettes MM
    Curr Opin Pharmacol; 2006 Dec; 6(6):598-605. PubMed ID: 16987706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic α Cell-Derived Glucagon-Related Peptides Are Required for β Cell Adaptation and Glucose Homeostasis.
    Traub S; Meier DT; Schulze F; Dror E; Nordmann TM; Goetz N; Koch N; Dalmas E; Stawiski M; Makshana V; Thorel F; Herrera PL; Böni-Schnetzler M; Donath MY
    Cell Rep; 2017 Mar; 18(13):3192-3203. PubMed ID: 28355570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes.
    Dalle S; Burcelin R; Gourdy P
    Cell Signal; 2013 Feb; 25(2):570-9. PubMed ID: 23159576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular glucose availability and glucagon-like peptide-1.
    Park JH; Earm YE; Song DK
    Prog Biophys Mol Biol; 2011 Nov; 107(2):286-92. PubMed ID: 21907232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.